COVID-19 has put several little-known pharma companies on the map. Going hand in hand with these nano-caps’ pursuit of coronavirus solutions, hopeful investors have sent the small players’ shares to previously unimaginable heights.Vaxart (VXRT) might be the purest example of this phenomenon. At the start of the year, the vaccine specialist’s market cap stood at $17.39 million, with each share going for $0.34. Fast forward to July 29, and the biotech is valued at $1.2 billion, with shares changing hands for $11 apiece, an increase of an amazing 3,135%.Vaxart is not an outlier, as several other names have also recorded …read more
Source:: Yahoo Finance
